These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 9529287)

  • 1. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.
    Kim TS; Moon WK; Lee DS; Chung JK; Lee MC; Youn YK; Oh SK; Choe KJ; Noh DY
    World J Surg; 2001 Jul; 25(7):829-34. PubMed ID: 11572019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
    Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
    Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of positron emission tomography in the follow-up for breast cancer.
    Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
    Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
    Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
    J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
    Nakamoto Y; Osman M; Wahl RL
    Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
    J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.